Objective: This paper describes the main types of economic evaluation techniques.
T here has been unprecedented progress in health care during the past few decades. However, as Clare Booth Luce once quipped, "No good deed goes unpunished." We face the myriad innovations before us with scarce resources (such as money, time, and personnel). Thus progress has also left us with difficult choices. Insatiable demands for new treatments and services compel society to make difficult choices.
How should the choices be made? It has been suggested that "methods such as 'what we did last time,' 'gut feelings,' and even 'educated guesses' are not always better than organized consideration of the factors involved in a decision to commit resources to one use instead of another" (1) . As a result, economic evaluation methods have been developed to help inform difficult choices by simultaneously considering costs and consequences of treatment interventions.
Many of the methods' names have become familiarcost-benefit analysis (CBA), cost-effectiveness analysis (CEA), and cost-utility analysis (CUA). Unfortunately, their meanings have not. When is CUA preferred to CBA? Can something be more costly and still be cost-effective? It is clear from the names of these economic evaluations that cost plays a prominent role. However, it is not as widely appreciated that the defining aspect of an economic evaluation has nothing to do with cost; it is how patient outcomes are treated that distinguishes one method from another. This paper describes the main types of economic evaluation techniques. We examine their strengths and limitations from theoretical and applied perspectives. Using a hypothetical example, we also review the reasoning underlying each method and consider how this can be used to decide when it is appropriate to use each method.
The Relativity of it All
Once an investigator decides to incorporate an economic evaluation into a study, an appropriate comparator must be identified. To use a manufacturing metaphor, the new treatment or intervention under study and its comparator(s) are competing factories with different production processes. When measuring the economic efficiency of each "factory," costs must be compared, relative to some measure of "output." In health services, the "output" is patient outcome or treatment effectiveness.
We use a hypothetical case as a vehicle for our discussion. Suppose a research team has been asked to evaluate a novel program of assertive community treatment (PACT) for homeless people with severe and persistent mental illness. In addition to the standard PACT team configuration (that is, a psychiatrist, nurses, social workers, a substance abuse specialist, a vocational specialist, and so forth), a specialized employment and housing (EH) component has been added. PACT-EH will be compared with an intensive case management (ICM) program that is currently serving a similar population of individuals.
Every type of economic evaluation seeks to simultaneously estimate the trade off associated with cost and effectiveness. To truly know whether we are getting "value for money" requires examining PACT-EH's extra cost ()C) and extra effect ()E), relative to ICM. The estimate of extra cost is made from the difference in average cost estimates. That is,
Similarly, the estimate of the extra effect comes from difference in the average effect estimates:
Economic evaluations such as CBA, CEA, and CUA differ only in how average effect is conceptualized.
The importance of the decision about how treatment consequences are considered cannot be overstated. The type of economic evaluation one conducts and how the results can be interpreted are both predicated on this decision.
Choosing the Economic Evaluation Method
The choice of economic evaluation method reflects a decision about what should represent "success" and how that success should be valued. Assume the research team has collected data for 2 health outcomes (HEALTH 1 and HEALTH 2 ), 1 housing outcome (HOUSING 1 ), and 2 employment outcomes (EARNINGS 1 and EARNINGS 2 ). Is it reasonable to choose just one outcome as the consequence of PACT-EH? Should all outcomes be used? If so, how should they be combined? The answers to these questions are reflected in the economic evaluation method chosen. Table 1 describes common types of economic evaluations from which an investigator might choose. The great variety has led to some confusion (2,3); articles in the medical literature do not always correctly identify the type of economic evaluation that was conducted (4). This is in spite of the many articles (5-16) and books (17) (18) (19) (20) (21) that have been written to introduce economic evaluation concepts. Often, the source of problems involves how patient outcomes or effects were handled in the analysis (2) . The remainder of the paper discusses how the different economic evaluation methods treat effects, the underlying rationale and limitations for each approach, and how estimates can be influenced.
Cost-Minimization Analysis
For the purposes of our example, suppose the average cost of PACT-EH is $55 000 and the average cost of ICM is $50 000 (Table 2 ). Thus DC = $5000 (that is, $55 000!$50 000). In cost-minimization analysis (CMA), we focus solely on differences in costs or DC. The choice of CMA implies that the investigator is certain there are no differences between PACT-EH and ICM in any of the patient outcomes. CMA answers the question, "Is the extra effectiveness worth the extra cost?" In this example, DC > 0 indicates that PACT-EH is relatively more expensive. A CMA cannot answer the question, "Is the extra effectiveness worth the extra cost?" because effectiveness is not examined (it is presumed to be equivalent).
Two health treatments that unequivocally produce equivalent patient outcomes are infrequently observed. Despite this fact, the "Which is cheaper" reasoning associated with CMA persists; some have suggested this may be especially pernicious in mental health (22) . In situations where there may be a difference in effectiveness (that is, DE ¹ 0), CMA is inappropriate because it will provide only one-half the picture; the cheaper option may harm the patient. Instead, researchers should adopt an economic evaluation that allows the competing treatments or interventions to have different effectiveness (that is, DE ¹ 0); the simplest of these types of economic evaluations is CEA.
Cost-Effectiveness Analysis
To answer the question "Is the treatment cost-effective?" one must do the following: first, estimate the extra cost ( DC); second, estimate the extra effect (DE); third, compute the extra cost per extra effect (DC/DE); and fourth, judge whether the trade off estimated in step 3 is worth it.
CMA is simply step 1. To the extent that patient outcomes associated with the treatments differ, it is unhelpful to focus health care discussions solely on cost. In the same way that cheaper is not always better, so too is cheaper not always cost-effective. A CMA is not a proper substitute for a CEA when there is an appreciated difference in patient outcomes.
CEA uses one outcome as a measure of "effect." Since 2 of the primary objectives of PACT-EH are stable housing and employment, our CEA should examine at least one of these outcomes. Suppose we decide to focus on the effect variable "Days of stable housing" (HOUSING 1 ). The extra gain ()E) would be expressed as the difference in stable housing associated with PACT-EH versus ICM (that is, the mean of HOUS-ING 1 for PACT-EH minus the mean of HOUSING 1 for ICM). The difference in average HOUSING 1 for PACT-EH and ICM is 10 days (from Table 2 , 310 -300 = 10 days).
Step 3 involves calculating the conventional CEA statistic known as the incremental cost-effectiveness ratio (ICER = DC/DE). The ICER describes the extra cost per one additional patient outcome. · There may be moral objections about the impact of ability to pay in the process of valuing the effects.
Cost-utility analysis (CUA)
Two effects (quality and length of life) whose product is taken as quality-adjusted life years (QALYs).
Patient outcomes involving both quality and length of life can be incorporated in the analysis. In theory, the QALY measure is "universal," so that very different programs evaluatedwith QALYs can be compared. This estimate indicates that, compared with ICM, PACT-EH costs an average of $500 additional dollars per one additional day of stable housing.
In many economic evaluations, the ICER indicates that a new treatment is relatively more costly (DC > 0) and relatively more effective (DE > 0) than usual care. In these situations, to label something cost-effective is to express a personal opinion about the ICER "price tag," based on the amount one is willing to pay to get an extra unit of effect. Forming an opinion about whether the ICER "price tag" represents a good value (step 4 of a CEA) generally involves a value judgment. According to the $500 daily estimate, PACT-EH is cost-effective if one believes the extra effect is worth the extra cost. The ICER is an estimate, not a decision about the cost and effect trade off. Ultimately, the decision maker is left with the responsibility for step 4 (that is, deciding whether the ICER represents a good deal; for example, is an additional day of stable housing worth $500?).
Further, while there is usually little controversy about how the outcome is measured for a CEA (for example, community tenure measured in days), there may be some concern regarding which outcome was chosen to represent success. Indeed, there may be many measures that could be selected as a reasonable effect of new treatment. This is especially true for a complex program with more than one objective, such as PACT-EH, where many outcome measures could be used and would yield different ICERs.
For example, we could have easily chosen our employment measures as an outcome, defining a new variable (total earnings) from the sum of EARNINGS 1 and EARNINGS 2 . Had we done that, we would have found that, compared with ICM, PACT-EH is associated with a $100 less in total earnings. In this case,
Notably, this ICER of -$50 means $50 spent for each additional dollar not earned, rather than $50 saved for each additional dollar earned. This difference in interpretation is important. Thus the separate parts of the ICER (that is, DC and DE) should always be reported. Likewise, although both scenarios result in a positive ICER, it is reasonable to expect that decision makers will care whether the treatment is more costly (DC > 0) and more effective (DE > 0) rather than less costly (DC < 0) and less effective (DE < 0). This can only be determined through a separate inspection of DC and DE. In addition, compared with the ICER calculated with HOUSING 1 as an outcome, the ICER calculated with total earnings, makes PACT-EH appear less attractive. Thus different ICERs generated from different outcome measures can yield different results. When reading economic evaluations, it is important to remember that a study's final conclusions may rest on which measure of effectiveness was chosen (for example, 23).
In general, the CEA approach offers a different perspective from only considering costs. With CMA, we know that PACT-EH is more expensive than ICM. With CEA, we also know about the trade off (that is, what additional effect is associated with the additional costs). However, we are still left with the question in step 4-is the trade off worth it? One way to incorporate the value judgments necessary to address step 4 is to use methods from CBA.
Cost-Benefit Analysis
There are 2 main characteristics that distinguish a CBA from a CEA. The first involves the number of patient outcomes Clearly, a challenge with "real world" CBA is getting the dollar value for the extra effect. While society might be able to attach a value to a new bridge, road, or airport, it may be more difficult to value a day without psychotic symptoms. Thus, not surprisingly, few CBAs have been done of mental health interventions (some exceptions include a seminal economic evaluation of PACT [24] and a CBA of nurse therapy for neuroses in primary care [25] ). CUA could be considered a compromise between CBA (where many outcomes are considered) and CEA (where only one outcome is considered).
Cost-Utility Analysis
When an economic evaluation focuses on a single outcome measured in convenient, natural units (such as length of life measured in years), it is a CEA. However, when the economic evaluation focuses on quality adjusted life years (QALYs), the economic evaluation is frequently described as a CUA.
The World Health Organization (WHO) uses disability adjusted life years (DALYs) to measure global burden of disease (26) (27) (28) (29) . Given the controversy surrounding DALYs (30) (31) (32) (33) is beyond the scope of this paper and given the fact that most mental health economic evaluations analyses use QALYs rather than DALYs, we refer readers interested in calculating and presenting DALYs elsewhere (34-37).
The Further, while there are various methods to calculate QALYs, there is no universally accepted standard. In fact, there is evidence that there are important differences in QALY estimates, depending on the methods used (37-39) and on whom the methods are used (for example, the patient, family, clinician, or general public) (40) . The advantage of a CUA is that the cost per QALY for a new mental health treatment or intervention can be compared with other health care interventions' cost per QALY "price tags." Some people feel that a mental health treatment with an ICER estimate of $20 000 to $40 000 per QALY "compares favorably to those for a wide range of preventive and therapeutic services"(22, p 1643). However, to enjoy this advantage, there is a risk of using an erroneous measure to elicit incorrect values from the wrong people.
treatment (for example, 41). If we had a sense of the range of society's willingness to pay for an additional QALY or day of stable housing, then we could compare this with our ICER "price tag." This could be done using a regression framework that allows for a variety of willingness to pay values (for example, $20 000 per QALY, $50 000 per QALY, and $100 000 per QALY) (42) . Often this speculative process is aided by appealing to previous funding decisions. For example, if the Ministry of Health (MOH) typically funds treatments/interventions/health technologies that are around $50 000 per additional QALY, perhaps they should fund PACT-EH as well. While this type of reasoning may help to provide context, some have argued that decisions made in this way will lead to uncontrolled growth in expenditures (43) (44) (45) , in the same way that most people do not have enough money to buy from every store every item that is "on sale" even though all items are "sale-priced."
Discussion and Conclusion
Borrowing from Dickens, we might describe this new century as the best of times and the worst. With respect to health care, we cannot afford to do all that we can do. Whether this is caused by lack of money, time, or labour, the fact remains that scarcity forces choice. The results of an economic evaluation can assist decision makers by providing estimates of how much we must give up (that is, the extra cost) for what we get (that is, the extra gain in patient outcome).
Strengths of an Economic Evaluation
One of the most useful aspects of an economic evaluation is the potential to evaluate costs and consequences systematically. It requires the researcher to clearly enumerate the costs and consequences being considered, as well as which methods will be used to analyze the data. Will costs be calculated using the human capital method or the friction cost method (46, 47) ? Will patient outcomes be determined using QALYs or DALYs? At the same time, this means that both cost and consequence data must be gathered (or estimated). This frequently requires program budgets to be released to the investigators. If it is a service program, workload measures will also be collected; this can create an additional burden on frontline staff and create resistance to the project (48) . These barriers can be overcome, but they demand a greater investment to develop mutual trust on the part of both the research team and the service providers than might otherwise be needed. Another powerful argument in favour of doing an economic evaluation is that it can summarize costs and consequences simultaneously in one number (for example, in an ICER). However, it is important to remember that cheaper is not always better. Researchers should heed the caution that "there is little point in spending money on something that is cheap if it provides no benefits" (49, p 740).
Limitations of an Economic Evaluation
The primary limitation of summarizing cost and consequences in an ICER "price tag" is that decision makers, assuming they find the economic evaluation useful (50), must still decide whether the extra gain associated with the new treatment is worth the extra cost. Another key limitation of economic evaluation is that it does not explicitly consider the decision maker's budget. As a result, a decision maker might deem new treatment cost-effective but too expensive to approve. A compromise to avoid this state of affairs happens in the pharmaceutical area, when products become listed as "limited use" on a formulary. To simplify exposition, the importance of statistics in economic evaluation has been omitted. Readers should be aware that economic estimates vary, and their uncertainty should be described using confidence intervals or with some other method (42) .
Advocating for Better Care
To successfully advocate on behalf of patients that extra money spent for extra benefit may be worthwhile, measures of costs and benefits must be considered simultaneously. For example, mental health economic evaluations frequently include the costs of hospitalization that occur during the treatment period. However, to claim that hospitalization is bad simply because it adds cost ignores the potential benefits of hospitalization. Since economic evaluations consider both costs and consequences, it is impossible to determine a priori whether new treatment with less hospitalization will be more economically attractive. Some hospitalizations are likely to be beneficial (such as necessary hospitalization), and some are not (such as unnecessary hospitalization). In either case, a "good" or a "bad" hospitalization uses scarce health care resources; ignoring the consequences of the hospitalization ignores the reason for and the impact of the "good" and "bad" characterization (51) . From the earlier discussion of CMA, it is clear that it is only proper to ignore outcomes when there are no differences between treatment options. Thus while additional psychiatric hospitalization may cost more ()C > 0), the additional gain in patient outcomes ()E) may be worthwhile. Clearly, this determination can only be made after )E is calculated and valued.
Using economic evaluation to analyze costs and consequences systematically and simultaneously, researchers can generate estimates (for example, $50 000 per extra QALY) upon which decision makers can render judgments (such as, "that's not economically attractive"). Conclusions : Les cliniciens doivent s'assurer que d'importants résultats des patients ne sont pas exclus des évaluations économiques. L'évaluation économique est un processus destiné à produire une estimation (plutôt qu'une décision). Un nouveau traitement peut être plus coûteux et être quand même rentable (si l'avantage additionnel vaut plus que le coût additionnel pour le produire). Cependant, puisque l'évaluation économique ne prend pas en compte explicitement le budget disponible d'un décideur, un nouveau traitement peut être jugé rentable mais trop coûteux pour être approuvé.
